Difference between revisions of "Sutimlimab (Enjaymo)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== Anti-C1s antibody ==Preliminary data== #'''CARDINAL:''' Röth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA,...") |
|||
| Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
#'''CARDINAL:''' Röth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Fruebis J, Jiang X, Lin S, Reuter C, Morales-Arias J, Hobbs W, Berentsen S. Sutimlimab in Cold Agglutinin Disease. N Engl J Med. 2021 Apr 8;384(14):1323-1334. [https://doi.org/10.1056/nejmoa2027760 link to original article] [https://pubmed.ncbi.nlm.nih.gov/33826820/ PubMed] NCT03347396 | #'''CARDINAL:''' Röth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Fruebis J, Jiang X, Lin S, Reuter C, Morales-Arias J, Hobbs W, Berentsen S. Sutimlimab in Cold Agglutinin Disease. N Engl J Med. 2021 Apr 8;384(14):1323-1334. [https://doi.org/10.1056/nejmoa2027760 link to original article] [https://pubmed.ncbi.nlm.nih.gov/33826820/ PubMed] NCT03347396 | ||
| + | |||
| + | =Investigational agents= | ||
| + | *[[Sutimlimab (BIVV009)]] | ||
| + | |||
| + | [[Category:Cold agglutinin disease regimens]] | ||
| + | [[Category:Disease-specific pages]] | ||
| + | [[Category:Complementopathies]] | ||
| + | [[Category:Hemolytic process]] | ||
==Also known as== | ==Also known as== | ||
Revision as of 14:39, 8 May 2021
Mechanism of action
Anti-C1s antibody
Preliminary data
- CARDINAL: Röth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Fruebis J, Jiang X, Lin S, Reuter C, Morales-Arias J, Hobbs W, Berentsen S. Sutimlimab in Cold Agglutinin Disease. N Engl J Med. 2021 Apr 8;384(14):1323-1334. link to original article PubMed NCT03347396
Investigational agents
Also known as
- Code name: BIVV009